Literature DB >> 400823

Central nervous system chloramphenicol concentration in premature infants.

L M Dunkle.   

Abstract

Four premature infants under 1,500 g were treated with parenteral chloramphenicol for central nervous system infections due to organisms resistant to the penicillins. Serum, cerebrospinal fluid (CSF), and ventricular fluid concentrations of chloramphenicol were measured frequently during therapy and were used to maintain drug dosages in the safe and therapeutic range. Concentrations of chloramphenicol in the lumbar CSF and ventricular fluid had a mean of 23.3 +/- 7.7 micrograms/ml, consistently greater than 45% of peak serum levels. These data show that chloramphenicol enters the CSF in both ventricular and lumbar regions in therapeutic concentrations when administered intravenously. The clinical usefulness of this drug remains to be investigated. The importance of monitoring serum drug levels during therapy is emphasized.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 400823      PMCID: PMC352258          DOI: 10.1128/AAC.13.3.427

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Safe and effective chloramphenicol dosages for premature infants.

Authors:  J E HODGMAN; L E BURNS
Journal:  Am J Dis Child       Date:  1961-02

2.  Kanamycin and gentamicin treatment of neonatal sepsis and meningitis.

Authors:  M J Chang; M Escobedo; D C Anderson; L Hillman; R D Feigin
Journal:  Pediatrics       Date:  1975-11       Impact factor: 7.124

3.  A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group.

Authors:  G H McCracken; S G Mize
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

4.  Studies on the concentrations of chloramphenicol in the serum and cerebrospinal fluid of neonates, infants, and small children. Reciprocal reactions between chloramphenicol, penicillin and phenobarbitone.

Authors:  A Windorfer; W Pringsheim
Journal:  Eur J Pediatr       Date:  1977-01-26       Impact factor: 3.183

  4 in total
  9 in total

1.  Modification of the colorimetric assay for chloramphenicol in the presence of bilirubin.

Authors:  E O Mason; S L Kaplan; C J Baker; D A Ritter
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

Review 2.  Chloramphenicol in the 1980s.

Authors:  I Shalit; M I Marks
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

3.  Paradox between the responses of Escherichia coli K1 to ampicillin and chloramphenicol in vitro and in vivo.

Authors:  K S Kim; M Manocchio; B F Anthony
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

4.  Chloramphenicol bioassay.

Authors:  R M Bannatyne; R Cheung
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate.

Authors:  P J Ambrose
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

6.  Chloramphenicol pharmacokinetics in Ethiopian children of differing nutritional status.

Authors:  M Eriksson; L Paalzow; P Bolme; T W Mariam
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Ventricular fluid levels of chloramphenicol in infants.

Authors:  R Yogev; T Williams
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

8.  Effect of growth phase on the bactericidal action of chloramphenicol against Haemophilus influenzae type b and Escherichia coli K-1.

Authors:  W E Feldman; N S Manning
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

9.  Mitochondrial dysfunction and impaired growth of glioblastoma cell lines caused by antimicrobial agents inducing ferroptosis under glucose starvation.

Authors:  Kenji Miki; Mikako Yagi; Koji Yoshimoto; Dongchon Kang; Takeshi Uchiumi
Journal:  Oncogenesis       Date:  2022-10-04       Impact factor: 6.524

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.